SARS Vaccine Development

摘要

Developing effective and safe vaccines is urgentlyneeded to prevent infection by severe acute respiratorysyndrome (SARS)–associated coronavirus (SARS-CoV).The inactivated SARS-CoV vaccine may be the first oneavailable for clinical use because it is easy to generate;however, safety is the main concern. The spike (S) proteinof SARS-CoV is the major inducer of neutralizing antibod-ies, and the receptor-binding domain (RBD) in the S1 sub-unit of S protein contains multiple conformationalneutralizing epitopes. This suggests that recombinant pro-teins containing RBD and vectors encoding the RBDsequence can be used to develop safe and effective SARSvaccines